By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel is divided on Georgia Capital (LON:CGEO), with concerns about the sustainability of private portfolio valuations and the potential impact of a liquidity crunch on the company's assets, despite strong operational performance.
Risk: The potential re-rating of private portfolio valuations in a liquidity crunch, which could widen the NAV discount and erode buyback accretion.
Opportunity: The strong operational performance of the private portfolio, particularly in the pharmacy and healthcare sectors.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
NAV update: NAV per share was flat in Q1 (up 2.1% in GBP) but management says NAV has recovered to deliver >9% year-to-date growth (9.2% in GEL), driven by a rebound in Lion Finance Group (LFG) share price and strong private-portfolio performance.
Strong operating momentum: Large private holdings reported an "exceptional" quarter with 13.7% top-line growth and 27% YoY EBITDA growth; portfolio highlights include pharmacy EBITDA +20.5% to a record GEL 29m, healthcare EBITDA +16% to GEL 27m, and insurance revenues +27% with profits +70%.
Returns and balance sheet: Georgia Capital repurchased $22m of shares in Q1 (475,000 shares), has bought back >one-third of issued capital and narrowed the NAV discount to 16%, while ending March with ~ $85m liquidity, $50m gross holdco debt (net cash ~ $35m) and guidance to continue buybacks, deleverage and collect >GEL 200m of dividends in 2026.
Georgia Capital (LON:CGEO) said its net asset value (NAV) per share was flat in the first quarter, while emphasizing strong operating momentum across its major private holdings and continued progress on share buybacks and deleveraging.
Q1 NAV and portfolio drivers
Management said NAV per share was unchanged in Q1, though it increased 2.1% in pound sterling terms. The company attributed the flat quarter primarily to a decline in the share price of Lion Finance Group (LFG) during the period. Management said LFG’s share price has since recovered, helping drive “more than 9%” NAV per share growth year-to-date, including 9.2% year-to-date growth in Georgian lari (GEL) terms.
In discussing the quarter’s NAV bridge, management said LFG contributed a negative 0.6% to NAV per share, while private large portfolio companies contributed nearly 3% positively. A change in valuation multiples was a nearly 1% negative, emerging and other portfolio companies declined by 0.5%, buybacks added 0.3%, operating expenses were a 0.3% drag, and “other” contributed 0.9%.
Management also pointed to an “exceptional” quarter for large portfolio companies, citing 13.7% top-line growth and 27% year-over-year EBITDA growth. The CEO said the company applies “pretty conservative” valuation multiples to private holdings and expects operating performance to support NAV growth over time.
The CEO described Georgia’s macro environment as “firing on all cylinders,” citing 7.5% real GDP growth in 2025 and monthly readings of 7.9% in January and 8.8% in February. He attributed some of the momentum to stronger trade and logistics activity and inward investment, including flows tied to regional geopolitical developments.
He highlighted record foreign exchange reserves of $6.3 billion and said the current account deficit reached what he described as Georgia’s lowest level in 35 years at -2.6%. Inflation was described as “manageable” at 4.3%, while the policy rate was said to be 8%.
Georgia Capital continued buying back shares in the quarter, repurchasing 475,000 shares. Management said buybacks totaled $22 million in value during Q1 and that, cumulatively, the company has bought back “more than one-third” of its issued share capital. The CEO said the company would continue buybacks and noted the NAV discount had narrowed to 16%, which he called a historically low level.
The company also updated investors on leverage and liquidity. Management said net capital commitments (NCC) were around the mid-single digits as a percentage of NAV, and reiterated its goal to eliminate holding company leverage. The CEO said gross holdco debt is $50 million and “we may delever it in this year.”
CFO Giorgi Baratashvili said that despite spending roughly $22 million on buybacks and paying a half-year bond coupon, Georgia Capital ended March with about $85 million of liquidity and $50 million of gross debt, implying net cash of around $35 million.
Portfolio company performance: pharmacy, healthcare, and insurance
Retail pharmacy. Retail pharmacy CEO Tornike (and Nikoloz Shurgaia, as introduced) said the business remained the largest player in Georgia’s organized retail pharmacy market with around 34% market share based on 2024 figures. He said retail accounts for around 85% of revenue, with two core brands (GPC and Pharmadepot) plus franchise brands The Body Shop and Alain Afflelou Optics, and operations in Armenia and Azerbaijan.
He said the group added five pharmacies in Q1 (including one in Armenia) and ended March 2026 with 458 pharmacies, 14 Body Shop stores, and five optics stores. Retail revenue rose 8.6% year-over-year, supported by 4.5% same-store revenue growth and an 11% increase in average bill size. Wholesale revenue grew 6.7%. Gross margin reached a record 34% in Q1 2026, up 1.7 percentage points year-over-year.
Pharmacy EBITDA rose 20.5% year-over-year to a record GEL 29 million. Tornike said EBITDA-to-cash conversion was 114%, above a 90% target, and leverage was “1 time” adjusted net debt to last-twelve-month EBITDA, below a 1.5x target.
Healthcare services. Management said outpatient revenue grew 17% in Q1 2026, lifting outpatient share of total revenue by 1.4 percentage points to 46.2%. The business cited several clinical capability additions, including neuronavigation in two large hospitals and catheterization labs in two regional hospitals, as well as opening what it said is Georgia’s first human milk bank in Batumi. The company also said it recruited more than 60 physicians in Q1 and expanded its lab retail network to 12 branches.
Healthcare EBITDA grew 16% year-over-year to GEL 27 million, with EBITDA margin rising to 20.4%. Hospital occupancy declined from 75% to 71%, which management attributed to a lighter flu season; it noted flu-related admissions typically carry above-average margins. On cash conversion, management said Q1 reflects seasonality in state collections and expects improvement in the second half of the year.
Insurance. The insurance CEO (also named Giorgi in the transcript) said insurance revenues increased 27% in Q1, while profits grew 70%, with record-high revenues “on the base of last year’s high results.” He said property and casualty (P&C) and medical insurance each had 34% market share. He reported P&C revenues up 13%, profits up 27%, and ROE at 32%. In medical insurance, he said revenues grew 37% and profits rose 200%, with ROE “almost 50%.”
He also pointed to a new requirement that foreigners entering Georgia must buy travel insurance, which he said added GEL 1.5 million of revenue. He said the insurance business paid GEL 5.5 million in dividends to Georgia Capital in Q1.
Valuation updates, dividends outlook, and strategic priorities
Baratashvili said Q1 and Q3 are in-house valuation quarters and that the portfolio value was around GEL 5 billion, split roughly evenly between LFG shares and private portfolio companies. He said valuation multiples were flat in healthcare services, while multiples in retail pharmacy and insurance decreased slightly despite strong performance; he said the declines were partly due to results running ahead of prior discounted cash flow assumptions and that multiples could recover if performance continues.
He said LFG value declined by about GEL 100 million during the quarter, with roughly half due to dividends and buyback dividends received and half due to share price and exchange-rate effects, along with a small reduction in stake from 16.9% to 16.6%. Large portfolio companies saw valuation gains in excess of GEL 150 million, which were partly offset by multiple changes. He added that “other portfolio companies” decreased by GEL 24 million, including an impact from discontinuing two renewable energy pipeline projects.
On income, Baratashvili said Georgia Capital still expects dividend inflows in excess of GEL 200 million in 2026 across public and private holdings. He said GEL 40 million had been received so far, from LFG and the insurance business, and that the pharmacy business would begin paying 2026 dividends in Q2.
During Q&A, management said it remains active on M&A in Georgia and is increasingly focused on Armenia, primarily through bolt-on acquisitions via existing portfolio companies. The CEO said the company does not view any holdings as “strategic assets,” adding, “if we can sell expensively, we sell it,” and stated a preference for divestments to strategic buyers when pricing is attractive. On buybacks, management argued the current discount remains accretive and said it plans to continue repurchases.
About Georgia Capital (LON:CGEO)
Georgia Capital PLC (“Georgia Capital” or “the Group” or “GCAP”– LSE: CGEO LN) is a platform for buying, building and developing businesses in Georgia with holdings in sectors that are expected to benefit from the continued growth and further diversification of the Georgian economy. The Group's focus is typically on larger-scale investment opportunities in Georgia, which have the potential to reach at least GEL 300 million equity value over 3-5 years from the initial investment and to monetise them through exits, as investments mature.
Four leading AI models discuss this article
"CGEO is successfully transitioning from a capital-intensive builder to a cash-generative holding company, making the current 16% NAV discount a compelling entry point for investors comfortable with frontier-market macro volatility."
Georgia Capital (LON:CGEO) is executing a textbook value-unlocking strategy, but investors should look past the headline EBITDA growth. The 16% NAV discount is attractive, but it is effectively a 'liquidity premium' for a holding company operating in a volatile frontier market. While the 27% EBITDA growth in private holdings is impressive, the reliance on internal valuations for half the portfolio creates a 'valuation circularity' risk. The management's shift toward aggressive divestments and buybacks is the right capital allocation move, yet the underlying sustainability of the Georgian macro-boom—heavily tied to regional geopolitical flows—remains the primary tail risk that could quickly reverse these gains.
The 'exceptional' EBITDA growth may be masking a reliance on unsustainable regional geopolitical tailwinds, and the internal valuation methodology for private holdings could be significantly overstating NAV if liquidity in the Georgian market dries up.
"Buybacks at 16% NAV discount plus 27% portfolio EBITDA growth should drive further multiple expansion and per-share NAV accretion."
Georgia Capital (LON:CGEO) delivered exceptional private portfolio momentum—13.7% top-line growth, 27% YoY EBITDA surge—with pharmacy EBITDA +20.5% to GEL29m record, healthcare +16% to GEL27m, insurance profits +70%. Q1 NAV flat but YTD +9.2% GEL amid LFG recovery; buybacks $22m (475k shares, >1/3 total capital repurchased) narrowed discount to 16%, accretive with net cash ~$35m vs $50m debt. Georgia macro solid (7.5% 2025 GDP forecast, reserves $6.3bn). Conservative multiples (flat/slightly down) suggest re-rating potential as >GEL200m 2026 dividends flow in.
LFG's Q1 -0.6% NAV drag highlights stake volatility (16.6% holding), while Caucasus geopolitics could unwind tourism/FDI gains tied to regional tensions. Private valuations risk compression if macro falters despite 'conservative' multiples.
"CGEO's private portfolio is performing exceptionally, but LFG's GEL 100m quarterly value decline and multiple compression across strong-performing assets suggest either cyclical macro peaks or hidden credit/market risks that buyback enthusiasm is masking."
Georgia Capital (CGEO) is executing disciplined capital allocation—$22m buybacks, 16% NAV discount (historically tight), net cash $35m—while portfolio companies deliver genuinely strong fundamentals: pharmacy EBITDA +20.5%, healthcare +16%, insurance profits +70%. The 9.2% YTD NAV growth in GEL is real. However, the article buries a critical risk: LFG (roughly 50% of portfolio value) declined GEL 100m in Q1 alone, and management attributes only half to dividends/buybacks—the rest to share price weakness. If LFG (a financial services play exposed to Georgia's credit cycle) continues deteriorating, it could overwhelm private portfolio gains. Also: multiples on pharmacy and insurance compressed despite strong earnings, suggesting either valuation discipline or market skepticism about sustainability.
The 27% EBITDA growth in private holdings and 9.2% YTD NAV recovery could be a sugar rush from Georgia's 8.8% February growth rate and geopolitical tailwinds (regional capital flows); if macro momentum stalls or LFG faces credit stress, the NAV multiple compression becomes a warning signal, not a buying opportunity.
"NAV momentum is fragile and overly reliant on a single private holder (LFG) and private-portfolio valuations; a re-pricing shock could erase most of the Q1/NAV gains."
Georgia Capital's Q1 results show NAV flat in USD but >9% YTD in GEL, driven by a rebound in Lion Finance Group and strong private-portfolio momentum (pharmacy, healthcare, insurance). Buybacks and deleveraging are supportive, yet NAV risk is concentrated: LFG drove a negative 0.6% in the NAV bridge while private holdings added about 3%. Missing context includes sensitivity to private-portfolio valuation multiples, GEL/GBP currency moves, and Georgia's macro cycle. 2026 dividends depend on ongoing portfolio performance and exits. Near-term upside looks plausible but fragile if private valuations or LFG performance disappoints.
The strongest counter is that the upside is highly contingent on LFG recovery and stable private-portfolio multiples; a stall or multiple compression could erase the Q1 NAV gains and widen the NAV discount again.
"CGEO's portfolio assets are highly correlated to systemic Georgian risk, rendering the NAV discount a permanent feature rather than a mispricing."
Claude highlights LFG's Q1 drag, but misses the deeper structural issue: CGEO is effectively a proxy for Georgian systemic risk masquerading as a diversified holding company. If LFG (the bank) suffers, the private portfolio's real estate and healthcare assets will simultaneously face liquidity crunches and credit contraction. The 'NAV discount' isn't just a liquidity premium; it is a rational market pricing of the inevitable correlation between these assets during a regional geopolitical shock.
"Private portfolio EBITDA resilience shows operational decoupling from LFG risks, bolstering buyback accretion."
Gemini, your systemic correlation thesis ignores the private portfolio's standalone strength: 27% EBITDA growth held firm amid LFG's GEL100m Q1 drop, with pharmacy (+20.5%) and healthcare (+16%) thriving on domestic demand less tied to credit cycles. Real estate may correlate, but buybacks at 16% discount provide a 20%+ NAV floor via accretion (475k shares repurchased). Decoupling evidence trumps assumed meltdown.
"Strong EBITDA growth doesn't protect against multiple compression if the market doubts sustainability—buyback accretion only works if you're buying at true discount to intrinsic value, not just to book NAV."
Grok's 20%+ NAV floor via buyback accretion assumes LFG stabilizes and private multiples hold. But Claude's observation that multiples *compressed* despite 27% EBITDA growth is the tell: the market isn't pricing in decoupling—it's pricing in skepticism about valuation sustainability. If pharmacy/healthcare multiples compress further (not just hold), buyback accretion evaporates. Grok conflates operational strength with valuation resilience; they're not the same.
"Private-portfolio valuation risk and liquidity shocks could erase NAV gains even with strong EBITDA, so buyback accretion and a decoupling thesis may not protect NAV in a stress scenario."
Private-portfolio valuation risk is the overlooked lever. Even with 27% EBITDA growth, NAV resilience hinges on exit marks for private holdings; in a liquidity crunch, private valuations can re-rate, widening the discount and eroding buyback accretion faster than EBITDA can compensate. LFG drag matters, but if Georgian private assets reprice, the decoupling thesis collapses and NAV could surprise to the downside.
The panel is divided on Georgia Capital (LON:CGEO), with concerns about the sustainability of private portfolio valuations and the potential impact of a liquidity crunch on the company's assets, despite strong operational performance.
The strong operational performance of the private portfolio, particularly in the pharmacy and healthcare sectors.
The potential re-rating of private portfolio valuations in a liquidity crunch, which could widen the NAV discount and erode buyback accretion.